African American children with B-acute lymphoblastic leukemia have lower survival rates compared with European American children. To discover race-specific genetic aberrations conferring population-specific risks, we performed a whole exome sequencing study. Although most genetic aberrations were shared between the 2 groups, few were specific to each race. Our study revealed genetic aberrations that provide clues to explain race specific leukemogenesis. Background: The survival of patients with B-acute lymphoblastic leukemia (B-ALL) is significantly lower in African American (AA) children compared with European American children (EA). Here, we present a whole exome sequencing (WES) study showing race-specific genetic variations that may play a role on the disparate outcomes among AA and EA children with B-ALL. Patients and Methods: Five AA and 15 EA patients ranging in age from 1 to 18 years were enrolled. The median blast percentage was 94.8% (range, 64.5%-99.9%). Frozen bone marrow aspirate was used to extract DNA, and WES was performed, focusing on race and B-ALL-specific germline mutations. Results: Most genetic variants (n ¼ 339) were shared between AA and EA children. Some genetic aberrations were only uniquely identified in AA (n ¼ 58) and others in EA (n ¼ 52) In AA, the genetic aberrations clustered in canonical pathways related to telomerase signaling and cancer signaling. In EA, the unique genetic aberration clustered in pathways related to stem cell pluripotency and hereditary cancer. Conclusions: Our study revealed aberrant genetic aberrations in signaling networks that may contribute to race-specific aspects of leukemogenesis. Our results suggest the value of WES as a tool for development of individual gene signatures and gene scores for AA and EA children afflicted by B-ALL. These findings may ultimately impact disease management and contribute to the elimination of disparate outcomes in AA children with B-ALL.
Introduction
B-acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy diagnosed in the United States. Leukemia accounts for almost one-third (29%) of all childhood cancers. About 3 of 4 leukemias among children and teens are acute lymphoblastic leukemia (ALL). 1 It is the leading cause of cancer-related death in now an overall 5-year survival rate of greater than 85%. 1 This is, in part, owing to advances in the efficacy of multi-agent chemotherapy and risk-based stratification of treatment intensity according to patient characteristics, biological features of the leukemia, and early response to treatment such as day 8 or 15 bone marrow. 3 These developments herald the promise and challenges of precisionmedicine strategies that integrate leukemia genomics into contemporary therapy. Despite this progress, there are unmet needs related to the treatment of pediatric patients with B-ALL based on racial and ethnic variability. Earlier studies have shown that survival rates differ between various racial and ethnic groups. In a multivariate analysis by Bhatia et al, survival rates between African American (AA), Hispanic, Asian, and European American (EA) children differed, with AA and Hispanic children experiencing worse outcomes. 4 AA children have significantly lower incidence and survival rates compared with EA children. 5, 6 These results suggest unidentified molecular factors may be at play in the lower survival rates of AA children and highlight the need for prospective investigative analysis. 7 Although inherited inter-individual genetic variations, often related to geographic ancestry of racial or ethnic groups, 8 can contribute to racial and ethnic differences, the contribution of genetic variations in "candidate" pathways to race disparities in ALL has given inconsistent results. 9 Our current understanding of the initiating events in leukemogenesis remains insufficient to explain the biology and the molecular basis of health disparities and resistance to treatment. High-throughput microarray, genotyping, and next generation sequencing (NGS) technologies have provided new insights into leukemogenesis, drug resistance, and host pharmacogenomics, which identified novel subtypes of leukemia and suggested potential targets for therapy. [10] [11] [12] The majority of patients with B-ALL harbor recurring structural chromosomal rearrangements that are important initiating events in leukemogenesis, 6 but are insufficient to explain the molecular basis of health disparities and resistance to therapy. Recent advances in genomic profiling of B-ALL, including genome-wide association studies (GWAS) led to further understanding of the genetic landscape of the disease and discovery of different genetic factors that might influence racial disparities. 6,9,13 GWAS have identified 5 genomic loci that may have a role in B-ALL pathogenesis. 9, [13] [14] [15] [16] A meta-analysis of candidate gene association studies identified 47 studies of polymorphic variation in 16 genes that may impact B-ALL risk and observed statistically significant (P < .05) associations in only 8 of the 25 polymorphic variations studied, with an estimated false-positive probability of greater than 0.2. 17 A study by Xu and colleagues revealed that 10 of the 49 ARID5B single nucleotide polymorphisms are associated with racial disparities in susceptibility to B-ALL between EA and Hispanics and were validated in subsequent work. 13, 18, 19 Thus, genetic polymorphisms can contribute to the biological basis of population-specific risk of B-ALL. These studies have identified potential therapeutic targets and driver mutations in childhood cancers. However, for dissecting the molecular basis of health disparities, there is currently no gold standard for an optimal study design or analytic strategy. Additionally, the current therapeutic success rate has been built on the use of cytotoxic chemotherapy and radiotherapies that are often associated with significant adverse effects and can ultimately reduce the quality of life for survivors.
In a population of AA and EA pediatric patients with B-ALL, we used whole exome sequencing (WES) to discover genomic alterations in a cohort of AA and EA children with B-ALL. We present a study showing race-specific genetic aberrations among AA and EA children with B-ALL. The clustering of these germline genetic variants in canonical pathway of leukemogenesis confer populationspecific risks.
Material and Methods

Patients
Institutional Review Board (IRB #2013 -0250) approval was obtained at the University of Mississippi Medical Center (UMMC) prior to the start of the study. Written informed consent was provided by a parent or guardian of each child. Twenty independent pediatric patients with B-ALL from UMMC with newly diagnosed disease were included in this study. The demographics of the patients including disease characteristics and other hematologic indicators, assessed by bone marrow differential counting are summarized in Table 1 . The age of children ranged between 1 and 18 years, with a median age of 4 years. Eleven (55%) of them were females, and 9 (45%) were males. Five (25%) were AA, and 15 (75%) were EA. Clinical history, hemogram, flow cytometry, immunophenotypic, morphologic, cytogenetic, and prior molecular data were reviewed. Only 1 patient in our study had a relapse after treatment and died at the end of 2017. The median percent cellularity present on the bone marrow samples was 100% (range, 70%-100%), with 100% (range, 100%-100%) in AA and 100% (range, 70%-100%) in EA. The median percent of blasts was 94.8% (range, 64.5%-99.0%), with 94.5% (range, 86.0%-98.5%) in AA and 95.0% (range, 64.5%-99.0%) in EA. Table 2 denotes B-ALL subtypes. Most of the patients received a regimen of 3 or 4 therapeutic agents, which included vincristine, pegylated Escherichia Coli asparaginase and dexamethasone/prednisone or vincristine, pegylated Escherichia Coli asparaginase, daunorubicin, and dexamethasone/prednisone. In addition, patients were given intrathecal cytarabine and methotrexate. Drug administration usually began 1 to 2 days after sample collection.
DNA Extraction and WES
Between 2013 and 2016, a bone marrow aspirate (5 mL) was collected at diagnosis per study protocol, and informed consents were obtained from all participants. Fresh bone marrow samples are commonly processed for utilization in molecular analyses including NGS. Samples for this study, however, were routinely frozen and stored upon collection. As frozen bone marrow samples can be utilized for DNA extraction and are compatible with WES, 20 Genetic Mutations in Pediatric B-ALL and Race Disparities ng total) and absence of RNA peaks in the Bioanalyzer indicated success in processing tested samples. Library preparation was completed at the Translational Genomics Core located at the Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA with the TruSeq Exome sample prep kit (Illumina) using 50 ng of DNA. The nucleic acids were mechanically fragmented (Covaris Inc.) to produce fragments of w150 bp. The fragments were purified, and through amplification steps, adapter sequences that contain indexes to allow the separation of the samples during the analysis step, were added. The library was amplified by polymerase chain reaction, and its quality was determined using the Agilent Bioanalyzer 2100 and quantified by fluorometric methods (Qubit).
The libraries were sequenced at a length of 2 Â 75 bp (paired-end protocol), which provided at least 75Â coverage (8 samples per run), using reagents and instructions from Illumina (TruSeq Exome). Briefly, pooled libraries (8 per pool) were adjusted to 1.8 pM and flushed through flow cells containing oligonucleotides complementary to the adapters. The pool was then "fixed" to the flow cell and amplified in situ. Each DNA molecule served as a template for cluster generation. After clustering, the samples were sequenced in a NextSeq500 Illumina sequencer. Base calling was performed using the SCS v2.10/RTA v1.9 software (Illumina).
Bioinformatics Analysis
The WES were analyzed by NGS pipelines, which have 3 steps, including mapping, improvement, and variant callings. First, all the fastq samples from Illumina NextSeq that pass the quality control (fastqc: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ ) were mapped to the human reference genome hg19 from UCSC by using the Burrows-Wheeler aligner (BWA, http://biobwa.sourceforge.net/), producing 4 pair-end BAM files for each Table 1 Results WES (w100-fold) was performed for DNA from frozen bone marrow obtained at diagnosis from 20 pediatric patients, 5 AA and 15 EA, treated at UMMC e Children Hospital for B-ALL between 2013 and 2016. To compare the population difference between AA and EA, we focused on germline mutation alterations because they can reflect population genetic information and can be inherited from the previous generation. To further distinguish the mutation types, we compared our results with the 565 most confident predisposition genes of pediatric cancer for germline mutations analysis. Those genes were summarized by Zhang et al 22 through the careful review of the American College of Medical Genetics and Genomics gene list and the PubMed literature searching. [22] [23] [24] [25] [26] We found 449 genes with germline mutations from our results overlapped with the 565 gene list. Most (n ¼ 339) were shared between AA and EA (Figure 1) , including those present in the anaplastic lymphoma receptor tyrosine kinase (ALK ) gene (Figure 2 ). We found some genetic aberrations were specific for AA (n ¼ 58), such as lipoma preferred partner gene (LPP) in 5 patients (Figure 2 ), TNF alpha induced protein 3 (TNFAIP3), and premelanosome protein (PMEL) in 4 patients. In addition, genetic aberrations specific for EA (n ¼ 52), such as leukemia inhibitory factor receptor (LIFR) were found in 8 patients, with 7 of these EA having a missense mutation at p.V785I in Exon 17 of the LIFR gene as shown in Figure 2 . The top most frequent genes with nonsynonymous race-specific germline aberrations are summarized in Table 3 . The top ranked annotated genetic variants for AA and EA are provided in the Supplemental files (AA.summary and EA.summary, in the online version).
We performed a pathway analysis in an effort to establish parameters related to the observed aberrations (Ingenuity Pathways). This analysis showed that, independent of race, pathways showing aberrations related to diseases and biological functions were related to cancer, hereditary disorders, organismal injury and abnormalities, and hematologic diseases. Interestingly, canonical pathways differed between AA (Table 4) and EA (Table 5 ). For AA, pathways related to telomerase signaling, stem cell pluripotency, cancer signaling, acute myeloid leukemia, and chronic myeloid leukemia signaling had a higher prevalence of germline aberrations. In EA, the aberrations were more prevalent in genes involved with stem cell pluripotency, hereditary cancer, homologous recombination, and cancer metastasis. 
Amit Reddy et al
Clinical Lymphoma, Myeloma & Leukemia December 2018 -e505
Discussion
The desire to understand the genetic basis of disparities in patients with B-ALL has been catalyzed in part by the use of highthroughput NGS technologies. 27 However, there is currently no standard for an optimal study design or analytic strategy for dissecting the molecular basis of health disparities. Using high throughput genotyping, multiple GWAS studies on pediatric patients with B-ALL have been completed, and many genetic susceptibility loci have been found in EA. 13, 28 However, studies on AA are lacking, and recent data suggests that not all risk alleles for B-ALL will be revealed by studies limited to EA. 13, [28] [29] [30] We sequenced whole exomes to dissect the molecular basis of health disparities in a small group of pediatric AA and EA patients with B-ALL. Our effort The prevalence of genetic aberrations may contribute to differences in incidences and outcomes between AA and EA children with B-ALL. 9 Aberrant biological networks revealed by our study provide information on distinguishing germline genes with race-specific nonsynonymous aberrations. These findings can provide clues to future studies aiming at relevant matters such as those related to establishment of somatic mutations. Genetic aberrations and signaling networks that may be involved in race-specific leukemogenesis. Examples (Figure 2 ) include LPP in AAs, and LIFR in EAs.
Variants in LPP were identified in all AA patients. LPP acts as a transcriptional co-activator in the cell nucleus and plays a role in cell migration. 31 LPP has been found to be upregulated in lipomas as it has a function in smooth muscle cells, and even though it has not been shown previously, 31, 32 our study suggests that LPP may play a role in race-specific leukemogenesis. The later could, of course, be owing to lack of sufficient published information on LPP. Variants in the LIFR were found in 8 of the 15 EA patients. Overexpression of LIFR has been associated with various solid tumors including breast, skin, colorectal, and nasopharyngeal cancers. 33 The involvement of these genes in pediatric patients with B-ALL has been reported. 13, 29, 30, 34 However, their applicability in anticipating race-specific disease is unknown. Limiting factors in our study are small sample size confined to one treatment location and the inability of comparison with normal population. These limitations precluded study of the race-specific risk of specific alleles in relation to normal population. In addition, we did not associate genetic variants with differential gene expressions and clinical data including the incidence of relapse.
Conclusions
In summary, our results suggest that it may be possible to develop clustering of race-associated WES gene signatures in pediatric patients with B-ALL that may improve their prognostic classification in bone marrow aspirates. In the future, the biomarker panel derived from this study may help guide risk stratification, drug development, and treatment decisions to help reduce health care disparities in AA and EA children with B-ALL.
Clinical Practice Points
This study will provide the basis for prognostic assay for B-ALL and generates a novel hypothesis in relation to the molecular biology underlying the increased occurrence of aggressive B-ALL in AA children. Our findings suggest the value of WES as a tool for development of individual gene signatures and gene scores for AA and EA children with B-ALL. Our study may ultimately impact targeted disease management and contribute to the reduction of disparate outcomes among children with B-ALL.
